Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Revolution Medicines, Inc. (RVMD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
26.10-1.55 (-5.61%)
At close: 04:00PM EST
26.10 0.00 (0.00%)
After hours: 06:03PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close27.65
Open27.79
Bid25.00 x 900
Ask35.00 x 800
Day's Range25.60 - 27.79
52 Week Range21.78 - 56.18
Volume659,164
Avg. Volume470,596
Market Cap1.917B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-21.25
Earnings DateAug 09, 2021 - Aug 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est33.00
  • GlobeNewswire

    Revolution Medicines to Participate in 4th Annual Evercore ISI HealthCONx Conference

    REDWOOD CITY, Calif., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that the company will participate in the 4th Annual Evercore ISI HealthCONx Conference. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a fireside ch

  • Zacks

    Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Lags Revenue Estimates

    Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of -16.13% and -88.59%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Revolution Medicines Reports Third Quarter Financial Results and Update on Corporate Progress

    RAS(ON) Inhibitor Development Candidates Targeting KRASG12C and RASMULTI Progressing Toward the Clinic; Company Showed Additional Preclinical Data Supporting Benefits and Differentiation Company Poised to Select Additional RAS(ON) Development Candidate in 2021; Mutant-Selective Inhibitors of KRASG13C and KRASG12D Showing Preclinical Promise Global Phase 2 Study, RMC-4630-03, Recruiting Patients to Evaluate RMC-4630 in Combination with Lumakras™ REDWOOD CITY, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE

Advertisement
Advertisement